| Literature DB >> 22459705 |
Xiying Fan1, Bhaskar Upadhyaya, Liming Wu, Christopher Koh, Mónica Santín-Durán, Stefania Pittaluga, Gulbu Uzel, David Kleiner, Ester Williams, Chi A Ma, Aaron Bodansky, Joao B Oliveira, Pamela Edmonds, Ronald Hornung, Duane W Wong, Ronald Fayer, Tom Fleisher, Theo Heller, Calman Prussin, Ashish Jain.
Abstract
X-linked hyper-IgM syndrome (XHM) is a combined immune deficiency disorder caused by mutations in CD40 ligand. We tested CP-870,893, a human CD40 agonist monoclonal antibody, in the treatment of two XHM patients with biliary Cryptosporidiosis. CP-870,893 activated B cells and APCs in vitro, restoring class switch recombination in XHM B cells and inducing cytokine secretion by monocytes. CP-870,893 infusions were well tolerated and showed significant activity in vivo, decreasing leukocyte concentration in peripheral blood. Although specific antibody responses were lacking, frequent dosing in one subject primed T cells to secrete IFN-g and suppressed oocyst shedding in the stool. Nevertheless, relapse occurred after discontinuation of therapy. The CD40 receptor was rapidly internalized following binding with CP-870,893, potentially explaining the limited capacity of CP-870,893 to mediate immune reconstitution. This study demonstrates that CP-870,893 suppressed oocysts shedding in XHM patients with biliary cryptosporidiosis. The continued study of CD40 agonists in XHM is warranted. Published by Elsevier Inc.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22459705 PMCID: PMC3365556 DOI: 10.1016/j.clim.2012.01.014
Source DB: PubMed Journal: Clin Immunol ISSN: 1521-6616 Impact factor: 3.969